Q1 2021

Filed May 13, 2021 · 10-Q · 43 days after period end · 0001140361-21-017275

Q1 2021 · 10-Q

Revenue—

Net Income

-$8.41M

no prior Q1 2020 on file

EPS Diluted

-$0.25

no prior Q1 2020 on file

Operating Income-$1,779,993—

Operating Cash Flow-$6,253,000—

Same quarter

no prior Q1 2020 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Mar 31, 2021 · filed May 13, 2021 · 43 d after period end

Nautilus Biotechnology, Inc. · CIK 1808805 · Engraved from SEC EDGAR